BCMA x CD3

Assets acting on this target.

Class
BCMA x CD3 T-cell engager

BCMA (B-cell maturation antigen) is a cell-surface protein expressed predominantly on plasma cells, the antibody-producing cells of the immune system, and is markedly overexpressed on malignant plasma cells in multiple myeloma. A BCMA x CD3 bispecific is an engineered antibody with two distinct binding arms: one recognizes BCMA on the tumor cell, the other recognizes CD3, a component of the T-cell receptor complex found on essentially all T cells. By binding both simultaneously, the molecule physically bridges a T cell to a myeloma cell, forming an immunological synapse that triggers T-cell activation independent of the T cell's native antigen specificity. This forces the immune system to attack tumor cells it would otherwise ignore, redirecting cytotoxic killing (via perforin and granzyme release) toward the cancer. The rationale for pairing BCMA with CD3 specifically is that BCMA's expression is largely confined to plasma cells, offering a reasonably selective tumor marker, while CD3 provides a universal handle on the T-cell compartment, allowing polyclonal T-cell recruitment without requiring prior tumor-specific immunity. This class of mechanism is broadly relevant to multiple myeloma and other plasma-cell disorders where BCMA is highly and consistently expressed.

By indication

Related mechanisms

BCMA x CD3 drugs compared

12 drugs, stage by indication
12 drugs acting on BCMA x CD3: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
ElranatamabPfizerbispecific antibody (T-cell engager)ApprovedApproved in Multiple Myeloma
LinvoseltamabRegeneron Pharmaceuticalsbispecific antibody (T-cell engager)ApprovedApproved in Multiple Myeloma
TeclistamabJohnson & Johnsonbispecific antibody (T-cell engager)ApprovedApproved in Multiple Myeloma
EtentamigAbbViebispecific antibodyPhase 3Phase 3 in AL Amyloidosis; Phase 3 in Multiple Myeloma
F182112Shandong New Time Pharmaceutical Co., Ltd.bispecific antibodyPhase 3Phase 3 in Multiple Myeloma
Gamgertamig (CM336)Gilead Sciences, Keymed Biosciences, Lakefront Biotherapeutics NVbispecific antibodyPhase 3Phase 3 in Multiple Myeloma
TorutamigBiocadbispecific antibodyPhase 3Phase 3 in Multiple Myeloma
TQB2934Sino Biopharmaceuticalbispecific antibodyPhase 3Phase 3 in Multiple Myeloma
Velinotamig (GR1803)Cullinan Therapeutics Inc., Genrix Bio, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.biologic (bispecific antibody, BCMA x CD3 T-cell engager)Phase 3Phase 3 in Multiple Myeloma
YKST02EXCYTE (Beijing) Pharmaceutical Technology Development Co., Ltd.bispecific antibodyPhase 2Phase 2 in Multiple Myeloma
VonsetamigRegeneron PharmaceuticalsNot recordedPhase 1/2Phase 1/2 in Multiple Myeloma; Phase 1 in Lupus Nephritis; Phase 1 in Systemic Lupus Erythematosus
cizutamigCandid Therapeutics, UCBT-cell engagerPhase 1Phase 1 in Systemic Lupus Erythematosus

← all mechanisms